Clinical Efficacy of Wangshi Baochi Pill Combined with Bifidobacterium Triple Viable in Treatment of Consti-pation Type of Irritable Bowel Syndrome
Objective To investigate the clinical efficacy and safety of Wangshi Baochi Pill combined with bifidobacterium triple viable capsule in the treatment of constipation type of irritable bowel syndrome(IBS-C).Methods Total 68 patients with IBS-C admitted to our hospital from May 2022 to May 2023 were randomly divided into treatment group and control group,with 34 cases in each group.The treatment group was treated with Wangshi Baochi Pill combined with bifidobacterium triple viable capsule orally,while the control group was treated with bifidobacterium triple viable capsule orally for 2 weeks continu-ously.The total effective rate,fecal trait scores,abdominal pain and abdominal distension scores before treatment and adverse reactions of the two groups were observed.Results The total effective rate was 91.1%in the treatment group,which was higher than 70.5%in the control group(P<0.05).After treatment,fecal trait and abdominal pain scores in the treatment group were better than those in the con-trol group(P<0.05).There was no significant difference in abdominal distension scores between the two groups(P>0.05).No adverse reactions occurred in both groups during treatment.Conclusion Wangshi Baochi Pill combined with bifidobacterium triple viable capsule for the treatment of IBS-C has good clinical efficacy and high safety,which is worthy of clinical promotion and application.
Constipation type of irritable bowel syndromeWangshi Baochi pillBifidobacterium triple viable capsuleEfficacy
NETL
NSTL
万方数据
